斯里兰卡急性冠脉综合征队列中阿托伐他汀40 mg与80 mg的疗效、安全性和成本效益比较:单中心随机对照临床试验方案
本方案计划在斯里兰卡一家三级医疗中心开展单中心、前瞻性、随机、对照、开放标签临床试验,纳入因新发急性冠脉综合征入院且未使用过他汀的患者,随机接受阿托伐他汀40 mg或80 mg加标准治疗。主要终点为12周时LDL-C≤70 mg/dL的患者百分比,按意向性治疗分析;次要结局包括安全性评估和成本效益评价,计算平均成本效果比和增量成本效果比。
要点
- 方案比较阿托伐他汀40 mg与80 mg在斯里兰卡急性冠脉综合征患者中的疗效、安全性和成本效益。
- 主要终点为12周时LDL-C≤70 mg/dL的患者百分比,按意向性治疗分析。
- 次要结局包括安全性评估及药物成本效果比和增量成本效果比。
核心结论
- 本试验将是南亚队列中阿托伐他汀40 mg与80 mg的首次头对头比较,结果将为南亚急性冠脉综合征患者处方阿托伐他汀40 mg的疗效和安全性提供证据。
研究设计与样本
- 单中心、前瞻性、随机、对照、开放标签临床试验,在斯里兰卡一家三级医疗中心开展,纳入因新发急性冠脉综合征入院且未使用过他汀的患者。
- 所有患者基线测量LDL-C,随机接受阿托伐他汀40 mg或80 mg加标准治疗,使用访谈员填写的表格收集数据。
- 患者在6、12和24周评估药物不良反应和LDL-C水平。
- 主要终点为12周时LDL-C≤70 mg/dL的患者百分比,按意向性治疗分析。
- 次要结局包括安全性评估和成本效益评价,收集药物费用包括服用片数,计算两种给药方案间的平均成本效果比和增量成本效果比。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Most guidelines recommend high-intensity statins for the secondary prevention of acute coronary syndrome (ACS). However, several studies from other Asian populations suggest enhanced sensitivity to statins, with effective low-density lipoprotein cholesterol (LDL-C) reduction seen at lower doses and possible higher incidence of adverse effects at higher statin doses. However, there is no published data from Sri Lanka. Therefore, we aimed to explore this hypothesis by comparing the efficacy, safety and cost-effectiveness of atorvastatin at doses of 40 mg and 80 mg in a cohort of South Asian individuals presenting with ACS from Sri Lanka. METHODS: This single-centre, prospective, randomised, controlled, open-label clinical trial is being conducted among patients naïve for statins admitted with incident ACS to a tertiary care setting in Sri Lanka. All patients will have LDL-C measured at baseline and are randomised to receive atorvastatin 40 mg or 80 mg in addition to standard of care. Data are collected using an interviewer-administered proforma. Patients are evaluated at 6, 12 and 24 weeks for adverse drug reactions and LDL-C level. The primary endpoint is the percentage of patients achieving LDL-C ≤ 70 mg/dL at 12 weeks. This outcome will be analysed by the intention-to-treat analysis. Secondary outcomes include safety assessments and a cost-effectiveness evaluation. For the latter, data on medication costs, including the number of tablets consumed, will be collected to calculate the average cost-effectiveness ratio and incremental cost-effectiveness ratio between the two dosing regimens. DISCUSSION: This will be the first head-to-head comparison of atorvastatin 40 mg and 80 mg in a South Asian cohort. The findings will provide evidence on efficacy and safety of prescribing atorvastatin 40 mg dose in South Asians with ACS. TRIAL REGISTRATION: Sri Lanka Clinical Trial Registry, SLCTR/2023/003. Registered on 03 March 2023, https://slctr.lk/trials/slctr-2023-003 .
引用
- Fernando K, Fernando N, Welhenge C, et al. Efficacy, safety and cost-effectiveness of 40 mg versus 80 mg atorvastatin in a Sri Lankan cohort with acute coronary syndrome: a protocol for a single-centre randomised controlled clinical trial. Trials. 2025. PMID: 40890828. doi:10.1186/s13063-025-08943-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。